Short answer
MIMEDX GROUP, INC. (MDXG) filed its Q1 2026 10-Q quarterly report on Apr 29, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $59M (down 33.1% year over year) with net income of −$11M.
Q1 2026 key financials · XBRL
- Revenue
- $59M
- −33.1% YoY
- Net income
- −$11M
- −254.6% YoY
- Operating margin
- -27.2%
- Gross margin
- 70.6%
- EPS (diluted)
- −$0.07
- −240.0% YoY
Source: XBRL data from the MIMEDX GROUP, INC. (MDXG) Q1 2026 10-Q on SEC EDGAR. USD.
MIMEDX GROUP, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $59.0M, down 33.1% YoY from $88.2M
- Gross margin 70.6% vs 81.2% YoY; net loss $10.9M vs net income $7.0M
- Best segment Surgical revenue $36.4M, up 13.2%; worst Wound revenue $22.6M, down 59.7%
- Cash $159.8M; operating cash flow $1.9M vs $5.3M YoY; $5.0M RegenKit-Wound Gel rights payment
- Medicare reimbursement changes reduced Wound pricing and volumes; liquidity expected sufficient for twelve months
Risk Factors
- No material changes to risk factors reported since the 2025 Form 10-K
- Carried-forward risks remain applicable across regulatory, operational, market, and financial categories
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MIMEDX GROUP, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.